Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SOUTH SAN FRANCISCO, Calif., March 05, 2018 -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ:GBT) today announced that on March 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 7,500 shares of the Company’s common stock with a per share exercise price of $58.80, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,950 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the "Plan").
The above-described awards were each granted as an inducement material to the employees’ entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock options and restricted stock unit awards described above) for issuance under the Plan, which was approved by the Company’s Board of Directors in January 2017.
About Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
